Faecal calprotectin in dermatology practice.
Biomarkers
/ analysis
Biopsy
/ standards
Colitis, Ulcerative
/ diagnosis
Colonoscopy
/ standards
Crohn Disease
/ diagnosis
Dermatology
/ standards
Feces
/ chemistry
Humans
Incidence
Inflammatory Bowel Diseases
/ complications
Leukocyte L1 Antigen Complex
/ analysis
Sensitivity and Specificity
Skin Diseases
/ epidemiology
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
accepted:
05
05
2020
pubmed:
25
6
2020
medline:
3
9
2021
entrez:
25
6
2020
Statut:
ppublish
Résumé
Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory condition of the bowel with two primary subtypes: Crohn disease and ulcerative colitis. Extraintestinal manifestations are common in IBD and, after musculoskeletal involvement, dermatological lesions are the most common. Currently, colonoscopy and biopsy are the most definitive tests for a diagnosis of IBD. However, in the past decade, faecal markers have emerged as new diagnostic tools to detect and monitor intestinal inflammation, and faecal calprotectin (FCP) in particular has gained popularity owing to its high sensitivity and specificity for detection of organic bowel disease. This review aims to explore whether there is a role for FCP measurement when encountering cutaneous manifestations associated with IBD.
Substances chimiques
Biomarkers
0
Leukocyte L1 Antigen Complex
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
831-835Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 British Association of Dermatologists.
Références
Greuter T, Navarine A, Vavricka SR. Skin manifestations of inflammatory bowel disease. Clin Rev Allergy Immunol 2017; 53: 413-27.
Al Roujayee A. Cutaneous manifestations of inflammatory bowel disease. Saudi J Gastroenterol 2007; 13: 159-62.
Mumolo MG, Bertani L, Ceccarelli L et al. From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol 2018; 24: 3681-94.
Sklow B. Perianal abscess/fistula disease. Clin Colon Rectal Surg 2007; 20: 102-9.
Ashok D, Kiely P. Bowel associated dermatosis-arthritis syndrome: a case report. J Med Case Reports 2007; 1: 81.
André M. Aseptic systemic abscesses. Orphanet encyclopedia, 2005. Available at: https://www.orpha.net/data/patho/GB/uk-aseptic-abscesses.pdf (accessed 6 December 2019).
Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol 2018; 154: 1417-23.
Cuquerella JT, Bosca-Watts MM, Ausejo RA et al. Amyloidosis in inflammatory bowel disease: a systematic review of epidemiology, clinical features, and treatment. J Crohn's Colitis 2016; 10: 1245-53.
Tozzo A, Negri MA, Salvatore S. Linear IgA bullous dermatosis associated with ulcerative colitis in a 14-year-old boy: a case report. J Clin Case Rep 2017; 7: 994.
Gill L, Zarbo A, Isedeh P et al. Comorbid autoimmune diseases in patients with vitiligo: a cross-sectional study. J Am Acad Dermatol 2016; 2: 295-302.
Chen W, Chi C. Association of hidradenitis suppurativa with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol 2019; 155: 1022-7.
Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J 2014; 90: 216-21.
Reddy H, Shipman AR, Wojnarowska F. Epidermolysis bullosa acquisita and inflammatory bowel disease: a review of the literature. Clin Exp Dermatol 2013; 38: 225-30.
Sanderson J, Nunes C, Escudier M et al. Oro-facial granulomatosis: Crohn's disease or a new inflammatory bowel disease? Inflamm Bowel Dis 2005; 11: 840-6.
Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005; 81: 580-5.
Jha AK, Chaudhary M, Dayal VM et al. Optimal cut-off value of fecal calprotectin for the evaluation of ulcerative colitis: an unsolved issue? JGH Open 2018; 2: 207-13.
Bjarnason I. The use of fecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2017; 13: 53-6.
National Institute for Health and Care Excellence. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. Available at: https://www.nice.org.uk/guidance/dg11 (accessed 1 October 2019).
Harris V, Smith SD. Chronic cheilitis: faecal calprotectin test a way to diagnose oral Crohn’s disease. Australas J Dermatol 2017; 58: 324-5.
Stingeni L, Tramontana M, Bassotti G et al. Pyodermatitis-pyostomatitis vegetans and antibullous pemphigoid antigen 180 autoantibodies: a casual association? Br J Dermatol 2015; 172: 811-13.
Scattoni R, Verrotti A, Rinaldi VE et al. Genital ulcer as a new clinical clue to PFAPA syndrome. Clin Exp Dermatol 2015; 40: 286-8.
Lalosevic J, Gajic-Veljic M, Nikolic M. Orofacial granulomatosis in a 12-year-old girl successfully treated with intravenous pulse corticosteroid therapy and chloroquine. Pediatr Dermatol 2017; 34: e324-7.
Lamb CA, Kennedy NA, Raine T et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68(Suppl): S1-106.
Provini LE, Stellar JJ, Stetzer MN et al. Combination hyperbaric oxygen therapy and ustekinumab for severe hidradenitis suppuritiva. Pediatr Dermatol 2019; 36: 381-3.
Rubino C, Paci M, Resti M et al. Late relapse of Henoch-Schönlein purpura in an adolescent presenting as severe gastroduodenitis. Front Pediatr 2018; 6: 355.
Özşeker B, Şahin C, Özşeker HS et al. The role of fecal calprotectin in evaluating intestinal involvement of Behçet’s disease. Dis Markers 2016; 2016: 5423043.
Furnari M, Savarino V, Savarino E. Fecal calprotectin in systemic sclerosis: light and shade of a promising tool. Autoimmun Rev 2016; 15: 1206-7.
Marie I, Leroi A-M, Menard J-F et al. Fecal calprotectin in systemic sclerosis and review of the literature. Autoimmun Rev 2015; 14: 547-54.
Adarsh MB, Dogra S, Vaiphei K et al. Evaluation of subclinical gut inflammation using faecal calprotectin levels and colonic mucosal biopsy in patients with psoriasis and psoriatic arthritis. Br J Dermatol 2019; 181: 401-2.
Schneider SL, Patel D, Shwayder T. Cutaneous manifestations of metastatic Crohn’s disease. Pediatr Dermatol 2018; 35: 566-74.
Shim TN, Doiron PR, Francis N et al. Penile lymphedema: approach to investigation and management. Clin Exp Dermatol 2019; 44: 20-31.
Paige DG, Leonard JN, Wojnarowska F, Fry L. Linear IgA disease and ulcerative colitis. Br J Dermatol 1997; 136: 779-82.
Weizman AV, Huang B, Targan S et al. Pyoderma gangrenosum among patients with inflammatory bowel disease: a descriptive cohort study. J Cut Med Surg 2015; 19: 125-31.